DIA: Driving Insights to Action
Science:Life Sciences
Cell and gene therapy are raising new ethical questions in clinical research and practice. “It will probably be the case that breast cancer, which now affects both wealthy people and poor people, will increasingly be a disease of poor people because wealthy people were able to get rid of the mutation from their families,” suggests Robert Klitzman, Professor of Psychiatry at the Columbia University College of Physicians and Surgeons and Director of the University’s Bioethics Masters and Certificate Programs. “Is this the kind of world we want, where wealthy people can afford to have better genes?”
New Sources Changing the Meaning of Evidence?
AI Research Can Optimize Clinical/Operational Effectiveness
Has Joining ICH Accelerated Innovation in China?
Pricing Pitfalls in Prescription Drug Advertising
MID-NET Among PMDA’s First Steps Into RWE
Regulatory Science 2019: Leading or Holding Back Innovation?
23andMe: Information Empowering Patient Action
The Patient’s Most Engaging Question: Why?
EUnetHTA: Post-Launch Critical for Comparative Data
HSA Harmonizing Culture and Science in Singapore
Promoting Patient-Centric Business: MedComm in Latin America
Separate but Equal: Regulatory & Pricing Assessments in EU
Genetics Leading Modern Revolution in Cancer Care
Automation No Substitute for Scientific Leadership
R2D2 & C-17 New Landmarks in Canada’s Collaborative Pathways
Advanced Therapies Moving Upon Combination Platforms
Challenges in Generic Drug Safety & Surveillance
Interview with a DIA 2018 Patient Scholar
Novel Approaches to PV Collaboration
Advancing the Science of Study Endpoints
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Speaking of Psychology